rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Milestone Scientific, Inc.

MLSS · NYSE American

Health CareMedical DevicesNot moving yet

MLSS stood above a rising 150-day average in 12 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 12.9% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$102K
Officials’ trades on record
0
Institutions holding
30 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 12 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$194K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months4
Buyers · sellers0 · 1

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders30+1 on the quarter
New · exited5 · 4
Reported value$1.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,073,166$665K+86,518+4.4%
Stonepine Capital Management, LLCnew · filed 14 Aug 2026666,666$349K+666,666
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026643,611$207K+26,966+4.4%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026464,449$149K+142,866+44.4%
STATE STREET CORPadded · filed 7 Aug 2026264,885$85K+125,000+89.4%
NFSG Corpadded · filed 14 Aug 2026141,000$45K+100,000+243.9%
NORTHERN TRUST CORPadded · filed 13 Aug 2026133,067$43K+20,452+18.2%
LPL Financial LLCunchanged · filed 7 Aug 2026124,945$40K00.0%
Mariner, LLCunchanged · filed 13 Aug 2026121,750$39K00.0%
World Investment Advisorsunchanged · filed 14 Aug 2026104,000$30K00.0%
31 Mar 2023 – 30 Jun 2026
222833Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

S.r.l. Bp4 Company insider10% owner · last 24 Oct 20251 · 34
Michael McGeehan Company insiderDirector · last 19 Dec 20241 · 4
Leonard Osser Company insiderDirector · last 22 Oct 20246 · 50
Benedetta I. Casamento Company insiderDirector · last 28 Aug 20240 · 0
Giandomenico Trombetta Company insiderDirector · last 28 Aug 20243 · 6
Neal I. Goldman Company insiderDirector · last 28 Aug 20249 · 0
Peter J. Milligan Company insiderPresident · last 1 Aug 20230 · 0
Jan Adriaan Haverhals Company insiderPresident · last 17 May 20230 · 0
Leslie Bernhard Company insiderDirector · last 19 Dec 20220 · 12
Leonard M. Schiller Company insiderDirector · last 13 Jun 20222 · 1
Company insiderCFO & COO · last 15 Jan 20210 · 24
Brent W. Johnston Company insiderPresident · last 13 Jul 20200 · 0

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%
PLSE Pulse BiosciencesLeading+42%
INFU InfuSystems HoldingsLeading+30%
SMTI Sanara MedTechLeading+26%
OBIO Orchestra BioMed HoldingsLeading+24%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202571.4%
Operating profit marginFY 2025 · to 31 Dec 2025-63.5%
Free cash flow marginFY 2025 · to 31 Dec 2025-32.7%
Return on capital employedFY 2025 · to 31 Dec 2025-155%
Research spendFY 2025 · to 31 Dec 20255.0%
Share count trendFY 2025 · to 31 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$1.1M
Free cash flowFY 2025 · to 31 Dec 2025−$2.9M

Analyst forecasts

No analyst forecasts yet.